" class="no-js "lang="en-US"> SomaLogic Announces Appointment of Adam Taich as Chief Business Officer - Medtech Alert
Friday, June 14, 2024

SomaLogic Announces Appointment of Adam Taich as Chief Business Officer

SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced that Adam Taich has joined the company as the Chief Business Officer.

In this newly created role, Adam will have broad responsibility across SomaLogic’s rapidly growing business to drive the company’s strategic and business development goals. He will also serve as a member of SomaLogic’s Executive Committee. Adam will report to SomaLogic Chief Executive Officer Roy Smythe, M.D.

“We are very pleased Adam has joined the SomaLogic team,” said SomaLogic Chief Executive Officer Roy Smythe, M.D. “His decades of leadership experience across a broad spectrum of life science commercial activities will be invaluable to us. I look forward to seeing him play an incredibly important role on our team as SomaLogic continues to rapidly scale and differentiate itself as the world’s leading proteomics company.

Adam’s career in the industry spans more than 20 years and includes a diverse set of roles in general management, corporate development and commercial operations. He most recently served as Vice President and General Manager of the Molecular Biology business of Thermo Fisher Scientific, where his portfolio included products sold into research, diagnostic and therapeutic markets. While at Thermo Fisher, he also led the Protein and Cell Analysis business, as well as led Strategy and Corporate Development for the Life Sciences Group.

“I’m extremely excited to join SomaLogic at such a critical stage in the evolution of the Company,” said Adam. “The SomaLogic team and the technology are well-poised to make a significant and lasting impact in the rapidly growing proteomics space.”

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more